Long term treatment of rheumatoid arthritis with rituximab

Autoimmunity Reviews

Volumn 8, Issue 7, 2009, Pages 591-594

  Caporali, Roberto ^a   Caprioli, Marta ^a   Bobbio Pallavicini, Francesca ^a   Bugatti, Serena ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

B lymphocyte; Rheumatoid arthritis; Rituximab

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

B LYMPHOCYTE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BINDING; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG USE; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; MONOTHERAPY; PATHOGENESIS; RELAPSE; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE DEPLETION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67349120767     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.02.008     Document Type: Review

References (40)

1. Cimmino M.A., Parisi M., Moggiana G., Mela G.S., and Accardo S. Prevalence of rheumatoid arthritis in Italy: the Chiavari Study. Ann Rheum Dis 57 (1998) 315-318
2. Bugatti S., Codullo V., Caporali R., and Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 7 (2007) 137-142
3. Samuels J., Ng Y.S., Coupillaud C., Paget D., and Meffre E. Human B cell tolerance and its failure in rheumatoid arthritis. Ann N Y Acad Sci 1062 (2005) 116-126
4. Silverman G.J., and Carson D.A. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 5 Suppl 4 (2003) S1-6
5. van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., de Jong B.A., Breedveld F.C., Verweij C.L., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective study. Arthritis Rheum 50 (2004) 709-715
6. Bobbio-Pallavicini F., Caporali R., Bugatti S., and Montecucco C. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies?. J Rheumatol 35 (2008) 1903-1905
7. Manzo A., Paoletti S., Carulli M., Blades M.C., Barone F., Yanni G., et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 35 (2005) 1347-1359
8. Panayi G.S. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?. Rheumatology (Oxford) 44 Suppl 2 (2005) ii3-ii7
9. Chesnut R.W., and Grey H.M. Antigen presentation by B cells and its significance in T-B interactions. Adv Immunol 39 (1986) 51-94
10. Mease P.J. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 35 (2008) 1245-1255
11. Lund F.E., Garvy B.A., Randall T.D., and Harris D.P. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 8 (2008) 25-54
12. Goronzy J.J., and Weyand C.M. Rheumatoid arthritis. Immunol Rev 204 (2005) 55-73
13. Blank M., and Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmun 28 (2007) 62-68
14. Putney Jr. J.W. TRP, inositol 1,4,5-trisphosphate receptors, and capacitative calcium entry. Proc Natl Acad Sci U S A 96 (1999) 14669-14671
15. Janas E., Priest R., Wilde J.I., White J.H., and Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 139 (2005) 439-446
16. Manadan A.M., and Block J.A. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. Am J Ther 15 (2008) 53-58
17. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (2000) 3900-3908
18. Protheroe A., Edwards J.C., Simmons A., Maclennan K., and Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford) 38 (1999) 1150-1152
19. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40 (2001) 205-211
20. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61 (2002) 883-888
21. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46 (2002) 2029-2033
22. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
23. Strand V., Balbir-Gurman A., Pavelka K., et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford) 45 (2006) 1505-1513
24. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
25. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
26. Keystone E.C., Emery P., Peterfy C.G., Tak P.P., Cohen S., Genovese M.C., et al. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68 (2008) 216-221
27. Salliot C., Dougados M., and Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 68 (2009) 25-32
28. Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum (Mar 11 2008) [Electronic publication ahead of print]
29. Caporali R., Caprioli M., Bobbio-Pallavicini F., and Montecucco C. DMARDS and infections in rheumatoid arthritis. Autoimmunity Rev 8 (2008) 139-143
30. Molloy E.S., and Calabrese L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmunity Rev 8 (2008) 144-146
31. Calabrese L.H., and Molloy E.S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67 Suppl 3 (2008) iii64-5
32. Sera T., Hiasa Y., Michitaka K., Konishi I., Matsuura K., Tokumoto Y., et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45 (2006) 721-724
33. Popa C., Leandro M.J., Cambridge G., and Edwards J.C. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46 (2007) 626-630
34. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56 (2007) 3896-3908
35. Genovese M., Emery P., and Ruderman E. Immunoglobulin levels and infection rates in patients with rheumatoid arthritis treated with rituximab (abstr). Arthritis Rheum 56 (2007) S149
36. Caporali R., Pallavicini F.B., Filippini M., Gorla R., Marchesoni A., Favalli E.G., et al. Treatment of rheumatoid arthritis with anti-TNF agents: a reappraisal. Autoimmunity Rev 8 (2009) 274-280
37. Hyrich K.L., Watson K.D., Isenberg D.A., and Symmons D.P. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 47 (2008) 1441-1443
38. Assous N., Gossec L., Dieudé P., Meyer O., Dougados M., Kahan A., et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 35 (2008) 31-34
39. McGonagle D., Tan A.L., Madden J., Taylor L., and Emery P. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) 47 (2008) 865-867
40. Atzeni F., Doria A., Maurizio T., and Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis?. Autoimmun Rev 6 (2007) 553-558